Mizuho lowered the firm’s price target on Kura Oncology (KURA) to $30 from $32 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q1 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology: Promising Clinical Trials and Stable Financials Justify Buy Rating
- Kura, Kyowa say ziftomenib abstract accepted for EHA Congress
- Kura Oncology’s Promising Market Position and Growth Prospects Justify Buy Rating
- Syndax price target raised to $17 from $16 at Scotiabank
- Kura Oncology’s Strategic Advancements and Promising Pipeline Drive Buy Rating